Previous 10 | Next 10 |
First-of-its-Kind Study in HIV Compares Ibalizumab Clinical Trial Experience to Matched Real-World Non-Ibalizumab OPERA ® Cohort Data Presented at ACTHIV ™ Conference Highlight Improved Clinical Outcomes of Ibalizumab for Heavily Treatment-Experienced ...
Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and improve efficacy for PD-L1 checkpoint inhibitor Additional in vivo data demonstrate significant activity of sudocetaxel zendusortide against SORT1+ triple-neg...
Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, w...
2023-04-12 11:51:09 ET Theratechnologies Inc. (THTX) Q1 2023 Earnings Conference Call April 12, 2023, 08:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer John Leasure - Global Commercia...
2023-04-12 07:34:09 ET Theratechnologies press release ( NASDAQ: THTX ): Q1 GAAP EPS of -$0.11 misses by $0.06 . Revenue of $19.9M (+7.2% Y/Y) misses by $1.3M . For further details see: Theratechnologies GAAP EPS of -$0.11 misses by $0.06, revenue of $19....
Q1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV ® Revenue and 5% Growth in Trogarzo ® Revenue Revised S udocetaxel Zendusortide (TH1902) Phase 1 Trial Protocol Expected to be Filed by End of Apr...
MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fir...
2023-03-07 06:20:33 ET Theratechnologies ( NASDAQ: THTX ) announces a receipt of notification letter from the Nasdaq dated March 3, 2023, advising that the Company was not in compliance with Listing Rule 5550(a)(2) as the bid price of listed securities had closed at less than ...
MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notif...
Theratechnologies Inc. (THTX) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Chief Financial Officer Christian Mar...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...